Objective-To examine the association between the serum lipoprotein (a) concentration and subsequent coronary heart disease.
Introduction
In recent years several case-control and angiographic studies have shown increased concentrations of serum lipoprotein (a) in men and women with coronary heart disease'6 and cerebrovascular disease.2 8 Despite the recent upsurge in interest in this lipoprotein, however, its function remains largely unknown.9 It is assembled from low density lipoprotein and a large hydrophilic glycoprotein, apolipoprotein (a) . The plasma lipoprotein (a) concentration is inherited as a quantitative genetic trait'" with a skewed distribution in white populations. Concentrations may vary from near zero to over 1000 mg/I. Lipoprotein (a) has been found in arterial walls," and a positive correlation between the serum lipoprotein (a) concentration and concentrations of lipoprotein (a) in arterial walls has been found in patients with coronary bypass grafts. The recent discoveries that apolipoprotein (a) is strongly homologous to plasminogen'" '" and that lipoprotein (a) and apolipoprotein (a) compete with plasminogen for binding to the plasminogen receptor"16 have stimulated further intensive research into the properties of this enigmatic lipoprotein.
There seems to be general agreement that lipoprotein (a) is associated with coronary atherosclerosis and myocardial infarction, but this has not been corroborated by prospective data. This study examines lipoprotein (a) concentrations in middle aged men who subsequently developed myocardial infarction during a follow up period of six years and compares these concentrations with those in controls of the same age who remained free of myocardial infarction.
Subjects and methods
In 1983 a random sample was drawn of half of all men in Gothenburg, Sweden, who were born in 1933 (that is, who were aged 50). All (8) 8X3 (9) 4-9 (1-7 to 145) Diabetes 11 5(3) taking a saluretic, and three were in men who were not currently being treated. Eight of the nine controls with hypertension were receiving f3 blockers. Plasma fibrinogen concentration, body mass index, waist to hip ratio, paternal history of myocardial infarction, and diabetes were not significantly associated with coronary heart disease.
Further to determine the relation between coronary heart disease and the serum lipoprotein (a) concentration the cases and controls were divided into fifths of lipoprotein (a) values (table III) . The association was slightly irregular, both the second and highest fifths of values being associated with a high proportion of cases. Among the seven cases in men with the second fifth of values, however, five were in smokers, whereas among the 10 cases in men with the highest fifth of values only four were in smokers. The proportion of cases of coronary heart disease in men with the highest fifth of values was more than twice that in men with the lowest four fifths of values considered together.
There was a positive correlation between the serum cholesterol concentration and the serum lipoprotein (a) concentration (r=0-18; p=0 04) and between systolic blood pressure and the serum lipoprotein (a) concentration (r=017; p=005). There were no other significant relations between lipoprotein (a) value and risk factors, including smoking, body mass index, and hypertension. A history of myocardial infarction in the mother was twice as common in men with the highest fifth of lipoprotein (a) concentrations, but this difference was not significant (p=0 37). Table IV gives the results of a multiple logistic regression analysis with coronary heart disease as the dependent variable and cholesterol concentration, body mass index, maternal history of myocardial infarction, smoking, treatment for hypertension, and serum lipoprotein (a) concentration as independent variables. Lipoprotein (a) concentration remained independently associated with coronary heart disease. Substituting triglyceride concentration for cholesterol concentration did not alter the results.
Of the 26 cases of coronary heart disease, only nine were in non-smokers; six of these were among the group with the highest fifth of serum lipoprotein (a) concentrations. Thus 23 of the 26 cases of coronary heart disease were characterised by occurring in smokers or men with raised serum lipoprotein (a) concentrations, or both. Of the remaining cases, one was in a diabetic subject and one in a man with uncontrolled hypertension at the time of screening.
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Discussion
This prospective study has shown an association between the serum lipoprotein (a) concentration and subsequent coronary heart disease in a general population sample of middle aged men and confirms earlier, retrospective case-control studies. Unlike other researchers2' 24 we did not find a strong association between high lipoprotein (a) concentrations in our subjects and coronary heart disease in parents, even though a maternal history ofmyocardial infarction was an independent risk factor for coronary heart disease in its own right. Our subjects, however, were middle aged men with parents at least in their 70s. We did not specify early myocardial infarction in the parents, which may account for the differences in comparison with other surveys. Also the disease state of the father was known in only 20 (a) concentration in samples with a low cholesterol concentration awaits further clarification by prospective data.
What are the public health implications of our findings? If the distribution of lipoprotein (a) values in the control group is taken to be representative of the total study group (n=757) the population attributable fraction may be calculated as 27% of all cases (seven extra cases in the group with the high lipoprotein (a) concentrations). Interestingly, the only other study which has considered population attributable risk for raised lipoprotein (a) concentrations (albeit with a lower cut off point for lipoprotein (a) concentration) reached almost exactly the same conclusion-namely, one in four myocardial infarctions in men under 60. 4 The attributable fraction of27% should be compared with the population attributable fraction for smoking, which was 46% for all participants in the study. Even though serum lipoprotein (a) concentrations have been shown to respond to pharmacological agents,26 it is unknown whether this influences outcome. Modifying the diet does not seem to lower the serum lipoprotein (a) concentration.27 In the absence of effective and harmless measures of intervention mass screening of lipoprotein (a) concentrations in the population is not warranted. In clinical practice, however, determining the lipoprotein (a) concentration may be useful in decisions about treatment for patients with other risk factors. The association between coronary heart disease and the lipoprotein (a) concentration at different levels of other cardiovascular risk factors remains to be determined in larger prospective studies. 
